The biomedicine subsidiary of Waigaoqiao Group has joined the Global Connect virtual innovation community platform, operated by Hong Kong Science and Technology Parks Corporation (HKSTP), and become a strategic partner.
This collaboration signifies a deep integration of Shanghai and Hong Kong’s biopharmaceutical innovation resources through a digital ecosystem, injecting new momentum into the global expansion of China’s biomedicine industry.
HKSTP is a comprehensive innovation ecosystem service provider based in Hong Kong with a global reach. Focusing on strategic emerging fields such as biomedicine, artificial intelligence, and new materials, it offers full-chain services including R&D space support, technology incubation, international resource matching, and policy advisory. To date, it has nurtured over 2,400 technology enterprises, helping innovative companies transition from early research to commercial implementation.
The Global Connect platform uses digital technology to create an online space dedicated to breaking down barriers of time and geography. Through interactive functions, it enables information exchange and resource coordination among institutions, facilitating cross-border innovation collaboration. The platform has already integrated innovation resources from over 100 countries and regions and attracted a diverse range of organizations. Within the biopharmaceutical sector, it has successfully nurtured a number of international R&D headquarters for leading enterprises, demonstrating strong capabilities in cutting-edge technology translation.
As the first state-owned professional services enterprise in Pudong to join the platform, Waigaoqiao Biomed will leverage the platform’s strengths to optimize its specialized service system for the biopharmaceutical industry.
This strategic partnership will focus on advancing cross-border collaboration in key areas such as cell and gene therapy and smart manufacturing of international medical devices. By integrating global network resources, it aims to help enterprises more efficiently access international advanced technologies and market opportunities, accelerating the global strategic layout of China’s innovative drugs and devices.
